Overview

Fludara (Oral) Phase II Study for Indolent Lymphoma

Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
To assess the antitumor effect and safety of Fludara in patients with indolent lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Fludarabine
Fludarabine phosphate
Vidarabine